Moderna postponed patent registration of the nCoV vaccine

The US pharmaceutical company said it would not patent its vaccine trials before the pandemic ended.

Moderna's announcement on October 8 is seen as a move to allow other drug manufacturers to develop injections using their technology.

Moderna did not claim intellectual property rights to its vaccine technology and filed for a patent after the actual pandemic ended. On the same day, the pharmaceutical company received a $ 56 million grant from the Defense Advanced Research Projects Agency (DARPA) to develop mobile manufacturing units to quickly produce vaccines and therapeutic drugs.

Moderna's vaccine was tested at the National Institutes of Health. Photo: NY Times.

Moderna is currently one of the farthest players in the nCoV vaccine race between US pharmaceutical companies. The company has previously received more than a billion dollars in funding from the government to develop and produce vaccine "candidate". In addition, Moderna also received another $ 1.5 billion package, aimed at serving the distribution and provisioning for US citizens.

Before the above move, on October 9, the World Health Organization (WHO) expressed support and welcomed this action by Moderna. On the other hand, the US pharmaceutical company is expected to apply for approval of its nCoV vaccine to regulatory authorities in Europe.

The European Pharmaceutical Regulatory Authority earlier this week released real-time reviews of Pfizer and BioNTech's Covid-19 vaccine, following a similar earlier announcement to AstraZeneca. The decision was made by Moderna just days after the European Drug Administration made a comprehensive assessment of other vaccine "competitors". Real-time evaluation can help speed up the successful vaccine approval process, by allowing researchers to send results in real time without waiting for studies to conclude.

Moderna said it is in talks with European countries and will send vaccine test data for approval. These data are also intended to be submitted to the US Food and Drug Administration (FDA) for approval to circulate in the home country.